Utility of carboplatin therapeutic drug monitoring for the treatment of neonate and infant retinoblastoma patients in the United Kingdom.
Gerard Cathal MillenAlice LawfordCatriona DuncanHelen JenkinsonGareth J VealShelby BarnettPublished in: British journal of cancer (2024)
Real time TDM is safe, effective and deliverable for neonates and infants receiving carboplatin for retinoblastoma and should be considered standard of care up to the age of 6 months.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- phase ii study
- palliative care
- prognostic factors
- randomized controlled trial
- squamous cell carcinoma
- quality improvement
- patient reported outcomes
- phase iii
- low birth weight
- chronic pain
- cross sectional
- preterm birth
- health insurance
- replacement therapy